These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16997309)

  • 1. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia.
    Nakamura T; Kodama Y; Takano H; Umetani K; Fujioka D; Saito Y; Kawabata K; Obata JE; Kitta Y; Kobayashi T; Mende A; Kugiyama K
    Atherosclerosis; 2007 Aug; 193(2):449-51. PubMed ID: 16997309
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Gómez-Gerique, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002;162:245-51.
    Moriarty PM; Backes JM
    Atherosclerosis; 2003 Jan; 166(1):201. PubMed ID: 12564455
    [No Abstract]   [Full Text] [Related]  

  • 3. [BECAIT [Bezafibrate Coronary Atherosclerosis Intervention Trial]].
    Yoshino G; Hirano T; Kazumi T
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():433-5. PubMed ID: 11347109
    [No Abstract]   [Full Text] [Related]  

  • 4. Chitotriosidase genotype and serum activity in subjects with combined hyperlipidemia: effect of the lipid-lowering agents, atorvastatin and bezafibrate.
    Canudas J; Cenarro A; Civeira F; Garcí-Otín AL; Arístegui R; Díaz C; Masramon X; Sol JM; Hernández G; Pocoví M
    Metabolism; 2001 Apr; 50(4):447-50. PubMed ID: 11288040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin and fibrinogen--a small subgroup shows extreme response.
    Sinzinger H; Rodrigues M
    Atherosclerosis; 1999 Aug; 145(2):415-7. PubMed ID: 10488971
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.
    Buldak L; Dulawa-Buldak A; Labuzek K; Okopien B
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):805-13. PubMed ID: 22943927
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.
    Arca M; Cambuli VM; Montali A; Sentinelli F; Filippi E; Campagna F; Quagliarini F; Antonini R; Romeo S; Baroni MG
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):660-6. PubMed ID: 19632099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of the efficacy of statin therapy in dyslipidemic diseases such as combined hypercholesterolemia IIA and hyperlipidemia].
    Liguori E; Sarcinella R
    Minerva Cardioangiol; 1998 Sep; 46(9):317-8. PubMed ID: 10021861
    [No Abstract]   [Full Text] [Related]  

  • 9. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia.
    Avisar I; Brook JG; Wolfovitz E
    Eur J Intern Med; 2008 May; 19(3):203-8. PubMed ID: 18395165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dramatic lowering of very high Lp(a) in response to niacin.
    Li M; Saeedi R; Rabkin SW; Frohlich J
    J Clin Lipidol; 2014; 8(4):448-50. PubMed ID: 25110227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of statin and fibrate combination therapy in lipid management.
    Kota SK; Meher LK; Rao ES; Jammula S; Modi KD
    Diabetes Metab Syndr; 2012; 6(3):173-4. PubMed ID: 23158983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Overviews of fibrate].
    Tada N
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():609-17. PubMed ID: 11347141
    [No Abstract]   [Full Text] [Related]  

  • 13. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 14. Reversal of atherosclerosis with aggressive lipid lowering.
    Farmer JA
    Curr Atheroscler Rep; 2005 Mar; 7(2):86-7. PubMed ID: 15727721
    [No Abstract]   [Full Text] [Related]  

  • 15. Genetic variation in the hepatic lipase gene is associated with combined hyperlipidemia, plasma lipid concentrations, and lipid-lowering drug response.
    Cenarro A; Artieda M; Gonzalvo C; Meriño-Ibarra E; Arístegui R; Gañán A; Díaz C; Sol JM; Pocoví M; Civeira F;
    Am Heart J; 2005 Dec; 150(6):1154-62. PubMed ID: 16338252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Drug combination therapies for patients with hyperlipidemia and its significance].
    Onuma T; Kawamori R
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():566-71. PubMed ID: 11347133
    [No Abstract]   [Full Text] [Related]  

  • 17. Reply: To PMID 25110227.
    Saeedi R; Li M; Rankin S; Frohlich J
    J Clin Lipidol; 2014; 8(6):647. PubMed ID: 25499950
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.
    Kurogi K; Sugiyama S; Sakamoto K; Tayama S; Nakamura S; Biwa T; Matsui K; Ogawa H;
    J Cardiol; 2013 Aug; 62(2):87-94. PubMed ID: 23672789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.
    Kawashiri MA; Kobayashi J; Nohara A; Noguchi T; Tada H; Nakanishi C; Inazu A; Mabuchi H; Yamagishi M
    Clin Chim Acta; 2011 May; 412(11-12):1068-75. PubMed ID: 21354122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-lowering medications: what the new guidelines and data mean to women.
    Schwartz JB
    J Gend Specif Med; 2001; 4(2):9-13. PubMed ID: 11480105
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.